Analyst Loss Discusses FDA Panal Review of Avandia

Loading player, please wait...
  • Info

  • Comments

July 14 (Bloomberg) -- Ira Loss, senior health-policy analyst at Washington Analysis Corp., talks with Bloomberg's Peter Cook about the outlook for a U.S. Food and Drug Administration advisory panel vote on GlaxoSmithKline Plc's diabetes drug Avandia. The FDA advisory panel decided today that Avandia increases the risk of cardiovascular side effects. The panel meeting in Gaithersburg, Maryland, will vote later on mortality and whether Avandia should be recalled. (Source: Bloomberg)

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change